October 01, 2025
BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) — Folia Health, the patient-driven health company and pioneer of home-reported outcomes (HROs), committed to transforming lived experiences into structured data insights to advance research and personalized care, today announced the close of a $10.5 million in Series A funding round led by S3 Ventures, alongside longtime partner Crosslink Capital and specialist fund Create Health Ventures. The investment will enable the company to double down on its mission to put power in the hands of patients, whose firsthand experiences with chronic and rare conditions make them valuable — and underutilized — healthcare experts.
Folia’s platform enables individuals to track symptoms, treatments, and outcomes, and share them with unprecedented control. The company’s commitment to consent and radical transparency means that any data used for external research requires explicit consent, participants can see exactly how their information is being used and what is being learned through detailed Participant Reports, and can withdraw participation at any time. Folia also recognizes participants for their contributions to research studies through its revenue-sharing program, Data Dividends.
“This funding is an affirmation of our fierce dedication to making patient-focused healthcare a reality. Instead of trying to fix the system from the outside in, we’ve built Folia to harness the power of each individual patient — to make their healthcare make sense,” said company founder and CEO Nell Meosky Luo. “People live in their bodies 24/7 — they notice patterns, track what works, spot when something’s off. Your own insights reveal your most burdensome symptoms, how different treatments and other things you’re trying are working for you; and also, the massive difference it can make when your treatments are working well. The knowledge held by each of our participants fills crucial knowledge gaps in traditional health data, which focuses on what happens when you’re at the clinic.” Read rest here.